HEP4_Therapeutic Target in Pulmonary Fibrosis
Research type
Research Study
Full title
Human Epididymis Protein 4: a Therapeutic Target in Pulmonary Fibrosis
IRAS ID
353543
Contact name
Paul Minnis
Contact email
Sponsor organisation
Northern Health and Social Care Trust
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Pulmonary fibrosis (PF) such as Idiopathic Pulmonary Fibrosis (IPF) and Systemic-Sclerosis-associated-Interstitial-Lung-Disease (SSc-ILD) are life-limiting lung diseases. There are limited therapies available and new treatments are urgently needed.
Studying PF is significantly hindered by reduced accessibility to lung fibroblasts. We have established a novel pre-clinical model of blood-derived induced pluripotent stem cells (iPSC). Using our patient-relevant disease model, we aim to characterize the fibrogenic and inflammatory effect of hypoxia-induced HE4 and identify the anti-fibrogenic and immunomodulatory effects of a repurposed diabetic drug Dapagliflozin.REC name
London - Riverside Research Ethics Committee
REC reference
25/PR/0102
Date of REC Opinion
28 Feb 2025
REC opinion
Further Information Favourable Opinion